1.
Bioorg Med Chem Lett
; 19(18): 5440-3, 2009 Sep 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-19674899
RESUMO
We have developed a family of 4-benzimidazolyl-N-piperazinethyl-pyrimidin-2-amines that are subnanomolar inhibitors of Lck. A subset of these Lck inhibitors, with heterocyclic substituents at the benzimidazole C5, are also low-nanomolar inhibitors of cellular IL2 release.